AN2 Therapeutics (ANTX) Liabilities and Shareholders Equity (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $87.5 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 7.56% year-over-year to $87.5 million in Q1 2026; TTM through Mar 2026 was $292.5 million, a 22.94% decrease from a year earlier, with the FY2025 full-year figure at $62.0 million, down 32.73% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $87.5 million, up from $62.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ANTX reached as high as $153.8 million in Q3 2023 and fell as low as $62.0 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $101.7 million across 5 years, with a median of $98.9 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity surged 57.02% in 2022 and sank 36.49% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $102.6 million in 2022, then surged by 35.28% to $138.7 million in 2023, then plunged by 33.63% to $92.1 million in 2024, then sank by 32.73% to $62.0 million in 2025, then jumped by 41.23% to $87.5 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $87.5 million in Q1 2026, $62.0 million in Q4 2025, and $67.2 million in Q3 2025.